Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with ⁹⁰Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI

Figure 3

Average ADC values measured at time points T₁ (a), T₂ (b), and T₃ (c) in lesions that were identified as regressive (light grey), stable (dark grey) and progressive (red) at long-term follow-up (T₃). Statistically significant differences are seen between regressive and progressive lesions at time point T₂ 48 hours after therapy () and between regressive lesions and the two other groups at time point T₃ around 10 weeks after therapy (regressive vs. stable: ; regressive vs. progressive: ). (c) Evolution of ADC values from T₁ via T₂ to T₃ for the three subgroups of lesions. Evidently, the increase in ADC that is measured between T₁ and T₃ for all subgroups already manifest as a trend at T₂, as early as 48 hours after treatment. It is most pronounced in regressive lesions. The asterisks indicate statistical significance.

(a)

(b)

(c)

(d)